<DOC>
	<DOCNO>NCT02451917</DOCNO>
	<brief_summary>Chronic kidney disease ( CKD ) one common microvascular complication diabetes mellitus , lead cause end stage renal disease develop country . The CKD diagnosis progression require re-evaluation hypoglycemic therapy constant dosing adjustment , order optimize glycemic control minimize side effect . Long act insulin analog pharmacokinetics study different stage kidney disease consensus define appropriate dose adjustment base glomerular filtration rate ( GFR ) . This research project compare glycemic response intensive insulin treatment NPH insulin basal insulin analog ( insulin glargine ) type 2 diabetes ( DM 2 ) patient CKD stag 3 4 . Patients method - Inclusion Criteria : DM 2 patient CKD secondary diabetic nephropathy GFR 15-59 ml/min/1.73m² . Exclusion Criteria : Patients systemic neoplasia , HIV , CKD nephropathy etiology , severe psychiatric disorder pregnant woman . Study design : This study consist randomize , cross-over , open-label control clinical trial . Patients randomly divide two group : GROUP 1 - insulin analog glargine day GROUP 2 - NPH human insulin , three application per day , group treat insulin lispro mealtime . The laboratory test perform baseline 3 , 6 , 9 12 month study start . During routine medical appointment analyze self- monitoring capillary blood glucose ( SMBG ) hypoglycemia score . After six month basal insulin change , i.e . patient use NPH insulin receive insulin glargine patient insulin glargine change NPH insulin . A CGMS carry 6 12 month . Methodology : The metabolic profile evaluate throughout SMBG ; biochemical , hormonal hematological measurement ; hypoglycemia score CGMS . Statistical analysis perform use comparative descriptive analyzes , chi-square distribution , t-test non-parametric test . Analyze data CGMS include area curve relate statistic . Finally , logistic regression model adopt evaluate effect treatment several variable question .</brief_summary>
	<brief_title>Glargine Versus NPH Patients With Chronic Kidney Disease</brief_title>
	<detailed_description>This study consist randomize , cross-over , open-label control clinical trial . Randomized patient allocate alternately two group receive follow therapy : GROUP 1 - insulin analog glargine day associate insulin lispro mealtime GROUP 2 - NPH human insulin , three application per day ( breakfast , lunch bedtime ) insulin lispro mealtime . Patients receive insulin NPH plus insulin lispro orient mix syringe breakfast lunchtime . The laboratory test perform baseline 3 , 6 , 9 12 month study start . During routine medical appointment patient bring self- monitoring capillary blood glucose ( SMBG ) , eight point per day week , hypoglycemia score . After six month insulin therapy , continuous glucose monitor system ( CGMS ) implement three day , , basal insulin change i.e . patient use NPH insulin receive insulin glargine patient insulin glargine change NPH insulin , group keep insulin lispro meal . A new CGMS carry six month therapy change . Methodology : The metabolic profile evaluate throughout SMBG ; biochemical , hormonal hematological measurement ; hypoglycemia score CGMS ( Medtronic/Northridge , CA ) . All randomize patient use least one dose study treatment consider Intent-to-treat ( ITT ) population . The initial plan randomize 40 patient , assume drop-out rate 15 % , obtain sample size least 34 randomized patient . .Statistical analysis perform use comparative descriptive analyzes , chi-square distribution , t-test non-parametric test . Analyze data CGMS include area curve relate statistic . Finally , logistic regression model adopt evaluate effect treatment several variable question .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>Patients type 2 diabetes mellitus chronic kidney disease secondary diabetic nephropathy stage 3 4 ( moderate severe nephropathy , correspond glomerular filtration rate 1559 ml/min/1.73m² ) include study . Patients systemic neoplasia , HIV , chronic kidney disease nephropathy etiology , severe psychiatric disorder pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Glargine insulin</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>CGMS</keyword>
</DOC>